Jul 9, 2024 Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
Mar 27, 2024 Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million